<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378625</url>
  </required_header>
  <id_info>
    <org_study_id>A00096/990954</org_study_id>
    <secondary_id>2229-04-10380</secondary_id>
    <nct_id>NCT00378625</nct_id>
  </id_info>
  <brief_title>Efficacy, Effect on Gametocytes and Tolerability of the Addition of Artesunate to Amodiaquine in Colombia</brief_title>
  <official_title>Randomised, Double Blind Clinical Trial of the Efficacy, Effect on Gametocytes and Tolerability of Amodiaquine Vs Amodiaquine Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Quibdo, Colombia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Internacional de Entrenamiento e Investigaciones Médicas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Internacional de Entrenamiento e Investigaciones Médicas</source>
  <brief_summary>
    <textblock>
      The primary goal of this study is to quantify the benefit of adding artesunate to amodiaquine&#xD;
      in treating patients with uncomplicated P. falciparum malaria, in a low transmission area in&#xD;
      Colombia. The benefit will be assessed in terms of:&#xD;
&#xD;
        -  Efficacy&#xD;
&#xD;
        -  Tolerability&#xD;
&#xD;
        -  Time of fever clearance&#xD;
&#xD;
        -  Time of parasite clearance&#xD;
&#xD;
        -  Proportion of gametocyte carriers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment failures</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>gametocyte carriage</measure>
  </primary_outcome>
  <enrollment>360</enrollment>
  <condition>Malaria,Falciparum</condition>
  <condition>Malaria</condition>
  <condition>Antimalarials</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. pure P. falciparum infection&#xD;
&#xD;
          2. parasitaemia &gt;500 and &lt;50,000 asexual parasites/μL (subsequently the lower limit was&#xD;
             modified to &gt;250 asexual parasites/μL)&#xD;
&#xD;
          3. age between 1 and 65 years old&#xD;
&#xD;
          4. availability to return for follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. history of allergy to the study drugs&#xD;
&#xD;
          3. history of taken complete treatment with an antimalarial drug in the previous 72 hours&#xD;
             or sulphas, clindamycin or tetracycline in the previous week&#xD;
&#xD;
          4. have a medical history of untreated hypertension or chronic heart, kidney or liver&#xD;
             disease&#xD;
&#xD;
          5. present any danger signs of severe malaria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyda Osorio, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Internacional de Entrenamiento e Investigaciones Médicas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Ismael Roldan and Centro de Salud San Vicente</name>
      <address>
        <city>Quibdo</city>
        <state>Choco</state>
        <zip>00</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 18, 2006</study_first_submitted>
  <study_first_submitted_qc>September 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2006</study_first_posted>
  <last_update_submitted>September 19, 2006</last_update_submitted>
  <last_update_submitted_qc>September 19, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

